Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Jefferies

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart

MarketBeat

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat

MarketBeat

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosi

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

MarketBeat

FIFA WC 2026 set to be a free kick for tourism, retail and clothing industry

Analysts said U.S. hotel operators Marriott, Hilton and Hyatt as well as online travel platforms Airbnb, Booking Holdings and Expedia are poised to benefit from the event. Marriott sees the World Cup-driven momentum to continue in the third quarter. Airbnb expects hosts in the New York-New Jersey area, Boston and…

The Economic Times

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

MarketBeat

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies

Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York. Payne described Arcturus as a “next generation messen

MarketBeat

Adani Power shares gain 3%, snap two-day losing streak. Why are Jefferies, Bernstein bullish on the stock?

Adani Power shares are climbing on strong prospects for India's power demand and the booming data centre sector. Analysts see the Adani Group well-positioned to capitalize on this growth. India's data centre industry is expected to expand rapidly. Rising electricity demand, driven by heatwaves and digital infrastructure needs, supports this…

The Economic Times

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

MarketBeat

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End

Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York. Speaking with Jefferies analyst Marco Baruzzi, Wessman said Alvotech ha

MarketBeat

Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure

Align Technology (NASDAQ:ALGN) CFO John Morici said the company continues to navigate a challenging but stable demand environment, with international markets and dental service organizations offsetting pressure in parts of North America. Speaking at the Jefferies Global Healthcare Conference in a f

MarketBeat

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions. Speaking at a Jefferies fireside c

MarketBeat

AVGO Stock Alert: Why Broadcom Is Leading Chip Stocks Lower Today

Broadcom shares sank and dragged the entire chip sector with them as the company missed on Q2 revenue and left AI guidance unchanged. Jefferies recommends buying the dip in AVGO stock.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune

MarketBeat

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted

The Economic Times

Jefferies initiates coverage on Poonawalla Fincorp with Buy rating. Why are analysts bullish?

Jefferies has initiated coverage on Poonawalla Fincorp with a Buy rating and a target price of Rs 490. The brokerage sees strong growth potential driven by a new leadership team and an expanded product range. Poonawalla Fincorp is expected to achieve the fastest AUM growth among major NBFCs. Profitability is…

The Economic Times

Is SaaSpocalypse real? CLSA says maybe not and here’s why

Initial fears of an "SaaSpocalypse" following Anthropic's AI plug-in release have subsided. Brokerages now suggest AI is driving a shift to consumption-based models, with IT firms partnering with SaaS providers poised to benefit from implementation demand. Systems of Record are seen as less vulnerable, while AI is expected to enhance…

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Jefferies raises Titagarh Rail target price by 23%. Check upside potential and key triggers

Titagarh Rail Systems shares rose after Jefferies increased its target price. The brokerage noted a strong quarter and improving execution. Titagarh is set to benefit from government infrastructure projects. The company expects to deliver more coaches and trains in the coming years. Margins improved significantly in the March quarter. Wagon…

The Economic Times

IndiGo soars 5% after Q4 results. What Goldman Sachs, Jefferies and others are saying

IndiGo's shares surged despite a Q4 FY26 net loss of Rs 2,536 crore, driven by Middle East conflict disruptions. Analysts remain largely positive, citing the airline's long-term growth strategy and India's strong domestic aviation demand, with several maintaining 'Buy' ratings and significant upside targets.

The Economic Times

Jupiter Wagons Q4 Results: Cons PAT tumbles 72% to Rs 29 crore, revenue falls 25% YoY

Jupiter Wagons saw its net profit drop 72% to Rs 29 crore in the March quarter. Revenue also fell 25% to Rs 780 crore. The company's EBITDA declined 46%. For the full year, profit after tax decreased 56%. Jupiter Wagons shares have seen a decline. Indian Railways plans a large…

The Economic Times

AI costs spiral as firms lose spending control

Companies are facing massive AI bills, with one firm reportedly spending $500 million in a month on Claude AI due to unchecked usage. Several global firms are now cutting back on AI spending, changing pricing, or rehiring engineers to manage ballooning costs, as AI currently costs more than it saves.

MarketBeat

AvePoint Conference: AI Governance Push Fuels AgentPulse Pipeline

AvePoint (NASDAQ:AVPT) executives said the company is broadening its position from its Microsoft roots into a wider data management, governance and AI security platform, with artificial intelligence driving new customer conversations and pipeline growth. Speaking at a Jefferies event hosted by anal

MarketBeat

AerSale Says Aging Fleets, Engine Shortages Keep Aviation Aftermarket Demand Strong

AerSale (NASDAQ:ASLE) Chief Financial Officer Martin Garmendia said the aviation aftermarket remains supported by aging fleets, strong passenger demand and supply chain constraints that are extending the service lives of existing aircraft. Speaking at Jefferies’ second annual MRO Summit, Garmendia

The Economic Times

Behind the petrol pump: Why fuel retailers losing Rs 7-8 per litre need $85 crude oil to stop bleeding cash

Oil companies face continued losses of Rs 7-8 per litre on petrol and diesel, with a breakeven point only at crude prices of $85-87 a barrel. Despite recent price hikes, government reluctance to reverse duty cuts and fiscal pressures mean OMCs are absorbing the pain, potentially impacting non-defence capital expenditure.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.